• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1998 - 2005年北加利福尼亚成人炎症性肠病治疗方法及治疗结果的时间趋势

Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005.

作者信息

Herrinton Lisa J, Liu Liyan, Fireman Bruce, Lewis James D, Allison James E, Flowers Nicole, Hutfless Susan, Velayos Fernando S, Abramson Oren, Altschuler Andrea, Perry Geraldine S

机构信息

Division of Research, Kaiser Permanente Northern California, Oakland, California 94612, USA.

出版信息

Gastroenterology. 2009 Aug;137(2):502-11. doi: 10.1053/j.gastro.2009.04.063. Epub 2009 May 13.

DOI:10.1053/j.gastro.2009.04.063
PMID:19445944
Abstract

BACKGROUND & AIMS: The management of inflammatory bowel disease (IBD) has become increasingly complicated, and it is unknown whether poor outcomes (prolonged steroid use, hospitalizations, and surgery) have declined in the general population.

METHODS

This multilevel study used computerized clinical data. The study comprised 2892 adults with Crohn's disease (CD) and 5895 with ulcerative colitis (UC) who received care at 16 medical centers within an integrated care organization in Northern California between 1998 and 2005.

RESULTS

Time trends included (1) a shift in gastroenterology-related visits from the gastroenterology division to primary care; (2) increased use of IBD-related drugs, except for a 7% decline in use of 5-aminosalicylate in CD and no change in steroid use for CD; (3) for the prevalence of prolonged steroid exposure (120 days of continuous use), a 36% decline for CD with a 27% increase for UC; (4) declines in the hospitalization rates of 33% for CD and 29% for UC; and (5) for the surgery rate, no significant change for CD with a 50% decline for UC.

CONCLUSIONS

Declines in prolonged steroid exposure and the hospitalization rate for CD and in the hospitalization and surgery rate for UC are encouraging; however, the increase in prolonged steroid exposure for UC merits concern and further investigation. The variability in care patterns observed in this study suggests lack of standardization of care and the opportunity to identify targets for quality improvement. These findings should stimulate research to quantify the effect of current trends in IBD management.

摘要

背景与目的

炎症性肠病(IBD)的管理日益复杂,目前尚不清楚总体人群中不良结局(长期使用类固醇、住院和手术)是否有所减少。

方法

这项多层次研究使用了计算机化临床数据。该研究纳入了1998年至2005年间在北加利福尼亚一个综合医疗组织内的16个医疗中心接受治疗的2892例克罗恩病(CD)成人患者和5895例溃疡性结肠炎(UC)成人患者。

结果

时间趋势包括:(1)与胃肠病学相关的就诊从胃肠病学部门转向初级保健;(2)IBD相关药物的使用增加,但CD患者中5-氨基水杨酸的使用下降了7%,CD患者中类固醇的使用没有变化;(3)对于长期类固醇暴露(连续使用120天)的患病率,CD患者下降了36%,UC患者增加了27%;(4)CD患者的住院率下降了33%,UC患者下降了29%;(5)对于手术率,CD患者无显著变化,UC患者下降了50%。

结论

CD患者长期类固醇暴露和住院率的下降以及UC患者住院率和手术率的下降令人鼓舞;然而,UC患者长期类固醇暴露的增加值得关注并需要进一步研究。本研究中观察到的护理模式差异表明护理缺乏标准化,并有机会确定质量改进的目标。这些发现应促使开展研究以量化IBD管理当前趋势的影响。

相似文献

1
Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005.1998 - 2005年北加利福尼亚成人炎症性肠病治疗方法及治疗结果的时间趋势
Gastroenterology. 2009 Aug;137(2):502-11. doi: 10.1053/j.gastro.2009.04.063. Epub 2009 May 13.
2
Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.猪鞭虫在治疗炎症性肠病方面似乎是安全的,并且可能有效。
Am J Gastroenterol. 2003 Sep;98(9):2034-41. doi: 10.1111/j.1572-0241.2003.07660.x.
3
Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study.加拿大炎症性肠病的住院率、手术率和再入院率:一项基于人群的研究。
Am J Gastroenterol. 2006 Jan;101(1):110-8. doi: 10.1111/j.1572-0241.2006.00330.x.
4
Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002.1996 - 2002年北加利福尼亚一个管理式医疗组织中炎症性肠病的发病率和患病率
Am J Gastroenterol. 2008 Aug;103(8):1998-2006. doi: 10.1111/j.1572-0241.2008.01960.x.
5
Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease.诊断时的表型及其他潜在预后因素对炎症性肠病病程的影响。
Am J Gastroenterol. 2009 Feb;104(2):371-83. doi: 10.1038/ajg.2008.38. Epub 2009 Jan 27.
6
Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis.基于马克夫分析的 948 例溃疡性结肠炎和克罗恩病患者的临床和经济结局的基于人群的欧洲队列研究。
Aliment Pharmacol Ther. 2010 Apr;31(7):735-44. doi: 10.1111/j.1365-2036.2009.04228.x. Epub 2009 Dec 29.
7
Adverse clinical phenotype in inflammatory bowel disease: a cross sectional study identifying factors potentially amenable to change.炎症性肠病的不良临床表型:一项识别潜在可改变因素的横断面研究。
J Gastroenterol Hepatol. 2010 Jul;25(7):1250-8. doi: 10.1111/j.1440-1746.2010.06302.x.
8
Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006.1996 年至 2006 年加利福尼亚北部儿童炎症性肠病的发病率、流行率和时间趋势。
J Pediatr. 2010 Aug;157(2):233-239.e1. doi: 10.1016/j.jpeds.2010.02.024. Epub 2010 Apr 18.
9
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.儿童及青年溃疡性结肠炎与克罗恩病的鉴别:北美儿科胃肠病学、肝病学和营养学会及美国克罗恩病和结肠炎基金会工作组报告
J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74. doi: 10.1097/MPG.0b013e31805563f3.
10
Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study).炎症性肠病发病后头五年内的诊断变化:一项前瞻性随访研究(IBSEN研究)的结果
Scand J Gastroenterol. 2006 Sep;41(9):1037-43. doi: 10.1080/00365520600554527.

引用本文的文献

1
Declining Corticosteroid Use for Inflammatory Bowel Disease Across Alberta: A Population-Based Cohort Study.阿尔伯塔省炎症性肠病患者皮质类固醇使用量下降:一项基于人群的队列研究。
J Can Assoc Gastroenterol. 2022 Jul 21;5(6):276-286. doi: 10.1093/jcag/gwac021. eCollection 2022 Dec.
2
Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study.在OCTAVE Sustain维持治疗研究中接受托法替布治疗的患者的无皮质类固醇疗效和安全性结果。
Therap Adv Gastroenterol. 2022 May 10;15:17562848221090834. doi: 10.1177/17562848221090834. eCollection 2022.
3
Epidemiology and Risk Factors of Portal Venous System Thrombosis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
炎症性肠病患者门静脉系统血栓形成的流行病学及危险因素:一项系统评价和Meta分析
Front Med (Lausanne). 2022 Jan 17;8:744505. doi: 10.3389/fmed.2021.744505. eCollection 2021.
4
Role of hospitalization for inflammatory bowel disease in the post-biologic era.生物制剂时代后炎症性肠病住院治疗的作用
World J Clin Cases. 2021 Sep 16;9(26):7632-7642. doi: 10.12998/wjcc.v9.i26.7632.
5
Immunosuppressed Patients with Crohn's Disease Are at Increased Risk of Postoperative Complications: Results from the ACS-NSQIP Database.免疫抑制的克罗恩病患者术后并发症风险增加:来自 ACS-NSQIP 数据库的结果。
J Gastrointest Surg. 2019 Jun;23(6):1188-1197. doi: 10.1007/s11605-019-04186-0. Epub 2019 Mar 18.
6
Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database.匈牙利生物时代新诊断克罗恩病患者的治疗偏好与结局:一项基于国家健康保险基金数据库的全国性研究
BMC Gastroenterol. 2018 Jan 30;18(1):23. doi: 10.1186/s12876-018-0746-6.
7
Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.与抗肿瘤坏死因子-α靶向治疗相比,延长皮质类固醇治疗与炎症性肠病的死亡率增加有关。
Am J Gastroenterol. 2018 Mar;113(3):405-417. doi: 10.1038/ajg.2017.479. Epub 2018 Jan 16.
8
Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study.克罗恩病的手术率正在下降:一项基于人群的时间趋势分析与验证研究
Am J Gastroenterol. 2017 Dec;112(12):1840-1848. doi: 10.1038/ajg.2017.394. Epub 2017 Oct 31.
9
Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.炎症性肠病中的结外癌症:来自 GETECCU Eneida 注册研究的数据。
Am J Gastroenterol. 2017 Jul;112(7):1135-1143. doi: 10.1038/ajg.2017.96. Epub 2017 May 23.
10
Care of inflammatory bowel disease patients in remission.缓解期炎症性肠病患者的护理。
Gastroenterol Rep (Oxf). 2016 Nov;4(4):261-271. doi: 10.1093/gastro/gow032. Epub 2016 Oct 10.